Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Usage Information

A selective human beta3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys.
M H Fisher, A M Amend, T J Bach, J M Barker, E J Brady, M R Candelore, D Carroll, M A Cascieri, S H Chiu, L Deng, M J Forrest, B Hegarty-Friscino, X M Guan, G J Hom, J E Hutchins, L J Kelly, R J Mathvink, J M Metzger, R R Miller, H O Ok, E R Parmee, R Saperstein, C D Strader, R A Stearns, D E MacIntyre
M H Fisher, A M Amend, T J Bach, J M Barker, E J Brady, M R Candelore, D Carroll, M A Cascieri, S H Chiu, L Deng, M J Forrest, B Hegarty-Friscino, X M Guan, G J Hom, J E Hutchins, L J Kelly, R J Mathvink, J M Metzger, R R Miller, H O Ok, E R Parmee, R Saperstein, C D Strader, R A Stearns, D E MacIntyre
View: Text | PDF
Research Article

A selective human beta3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys.

  • Text
  • PDF
Abstract

Activation of beta3 adrenergic receptors on the surface of adipocytes leads to increases in intracellular cAMP and stimulation of lipolysis. In brown adipose tissue, this serves to up-regulate and activate the mitochondrial uncoupling protein 1, which mediates a proton conductance pathway that uncouples oxidative phosphorylation, leading to a net increase in energy expenditure. While chronic treatment with beta3 agonists in nonprimate species leads to uncoupling protein 1 up-regulation and weight loss, the relevance of this mechanism to energy metabolism in primates, which have much lower levels of brown adipose tissue, has been questioned. With the discovery of L-755,507, a potent and selective partial agonist for both human and rhesus beta3 receptors, we now demonstrate that acute exposure of rhesus monkeys to a beta3 agonist elicits lipolysis and metabolic rate elevation, and that chronic exposure increases uncoupling protein 1 expression in rhesus brown adipose tissue. These data suggest a role for beta3 agonists in the treatment of human obesity.

Authors

M H Fisher, A M Amend, T J Bach, J M Barker, E J Brady, M R Candelore, D Carroll, M A Cascieri, S H Chiu, L Deng, M J Forrest, B Hegarty-Friscino, X M Guan, G J Hom, J E Hutchins, L J Kelly, R J Mathvink, J M Metzger, R R Miller, H O Ok, E R Parmee, R Saperstein, C D Strader, R A Stearns, D E MacIntyre

×

Usage data is cumulative from May 2025 through May 2026.

Usage JCI PMC
Text version 507 139
PDF 145 41
Citation downloads 144 0
Totals 796 180
Total Views 976
(Click and drag on plot area to zoom in. Click legend items above to toggle)

Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.

Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.

Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts